RT @agingdoc1: Upregulated Methylation Increases Expression And Proliferation Of Cancer Cells?? (2016). https://t.co/vzf4RWvp8B [Followin…
Upregulated Methylation Increases Expression And Proliferation Of Cancer Cells?? (2016). https://t.co/vzf4RWvp8B [Following reading the 2016 #scicomm, see the quoted 2020 study: "This small study did not establish a superior efficacy with addition of LMF
RT @agingdoc1: Phase I Study of High-Dose l-Methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH Wild-Type High-G…
Phase I Study of High-Dose l-Methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH Wild-Type High-Grade Glioma https://t.co/w2tBxC68MR
RT @VUMCneurology: *For the first time in a human study, the DNA methylome of high-grade glioma was reprogrammed after l-methylfolate (LMF)…
RT @VUMCneurology: *For the first time in a human study, the DNA methylome of high-grade glioma was reprogrammed after l-methylfolate (LMF)…
RT @vandy_biostat: Assistant prof & Academy for Excellence in Education member Tom Stewart is second author on this, in collaboration with…
RT @vandy_biostat: Assistant prof & Academy for Excellence in Education member Tom Stewart is second author on this, in collaboration with…
RT @vandy_biostat: Assistant prof & Academy for Excellence in Education member Tom Stewart is second author on this, in collaboration with…
Assistant prof & Academy for Excellence in Education member Tom Stewart is second author on this, in collaboration with @YaleMedicine @TNOncology @NeurosurgUCSF @hudsonalpha @CDGenomics2005 @GeiselMed and more. #cancer #Glioblastoma #SurvivalAnalysis #
*For the first time in a human study, the DNA methylome of high-grade glioma was reprogrammed after l-methylfolate (LMF) treatment. Such treatment might be useful in methylome priming prior to immunotherapy. @vandy_biostat @VUMCPathology @VUMC_Neurosurg ht
RT @CRC_AACR: #ICYMI: Phase I Study of #Methylfolate in Recurrent High-Grade #Glioma by Salas et al. https://t.co/afrHEl5DHr @GeiselMed @V…
#ICYMI: Phase I Study of #Methylfolate in Recurrent High-Grade #Glioma by Salas et al. https://t.co/afrHEl5DHr @GeiselMed @VUMChealth #glioblastoma #ASCO22 https://t.co/Slr8CzvPx5
Co-authors include assistant professor Thomas Stewart, who was recently elected to the Academy for Excellence in Education. #glioblastoma #SurvivalAnalysis #CancerResearch #genomics
RT @VUMCneurology: For the first time in a human study, the DNA methylome of high-grade glioma was reprogrammed after l-methylfolate (LMF)…
For the first time in a human study, the DNA methylome of high-grade glioma was reprogrammed after l-methylfolate (LMF) treatment. Such treatment might be useful in methylome priming prior to immunotherapy. @vandy_biostat @VUMCPathology @VUMC_Neurosurg htt
Our research was featured at the #AACR22. Very honored. @CancerDartmouth @QBSdartmouth @DartmouthNeuro @GeiselMed
RT @CRC_AACR: Watching the #AACR22 session on #glioblastoma? Read the paper reporting the potential of L-methylfolate-mediated methylome re…
Watching the #AACR22 session on #glioblastoma? Read the paper reporting the potential of L-methylfolate-mediated methylome reprogramming in patients with #HGG by @lsalas_epigenet, Stephen Clark, and colleagues. https://t.co/A0nRUcQRdp @VUMCneurology @Canc
Phase I Study of High-Dose l-Methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH Wild-Type High-Grade Glioma | Cancer Research Communications | American Association for Cancer Research https://t.co/PHJq5XtOLU
@antonioregalado Any cell can be re/programmed (with the right means) Antonio. Even cancer cells. https://t.co/BkxRu5psem
RT @EPIGENETICA47: The DNA methylome of high-grade glioma can be reprogrammed. Given the emerging role of epigenetic treatments in immuno-o…
The DNA methylome of high-grade glioma can be reprogrammed. Given the emerging role of epigenetic treatments in immuno-oncology. @CRC_AACR #EpigeneticReprogramming https://t.co/pQEKl0Tkkm https://t.co/EsXRSTdThE
RT @CRC_AACR: Read the Phase I Study of #Methylfolate in Recurrent High-Grade #Glioma by Salas et al. https://t.co/ZV4S6UaqI3 @GeiselMed @V…
Read the Phase I Study of #Methylfolate in Recurrent High-Grade #Glioma by Salas et al. https://t.co/ZV4S6UaqI3 @GeiselMed @VUMChealth #openaccess #glioblastoma https://t.co/luJm7Zeo97
Phase I Study of High-Dose l-Methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH Wild-Type High-Grade Glioma #GBM #cfDNAm #JPM2022 cc @BluestarGenomix @REALMIDx HT @genengnews https://t.co/VOi5BBFMVj https://t.co/ThmMkV5t2S
#brain #tumor stuff: #DNA Methylome Can Be Modified in #Glioblastoma https://t.co/xZF5BGt6IU original paper: https://t.co/KzS7Rd3XMt #methylfolate #cancer #brainturmor https://t.co/7LRng1juHq
RT @lsalas_epigenet: Our new paper is out. A DNA methylation modifier medication in recurring GBM. Some exciting results from a Phase I tri…
This study: https://t.co/bGxjDhUZls
RT @lsalas_epigenet: Our new paper is out. A DNA methylation modifier medication in recurring GBM. Some exciting results from a Phase I tri…
RT @OrdoFibonacci: Phase I Study of High-Dose l-Methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH Wild-Type Hi…
RT @CancerDartmouth: New paper by @lsalas_epigenet and @brockclarke with @vumchealth. Drug modifies epigenome in aggressive brain tumors. h…
Happy to start this 2022 with a great paper by IND faculty @lsalas_epigenet
Phase I Study of High-Dose l-Methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH Wild-Type High-Grade Glioma | Cancer Research Communications | American Association for Cancer Research https://t.co/DNLsN9WlB4
RT @lsalas_epigenet: Our new paper is out. A DNA methylation modifier medication in recurring GBM. Some exciting results from a Phase I tri…
Our new paper is out. A DNA methylation modifier medication in recurring GBM. Some exciting results from a Phase I trial. Still a long way to go, but more avenues opening for treatment in the future.
New paper by @lsalas_epigenet and @brockclarke with @vumchealth. Drug modifies epigenome in aggressive brain tumors. https://t.co/L3UcVpx4ZG
Phase I Study of High-Dose l-Methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH Wild-Type High-Grade Glioma | Cancer Research Communications | American Association for Cancer Research https://t.co/YDbsVyIss2
RT @CRC_AACR: Just published! Phase I Study of #Methylfolate in Recurrent High-Grade #Glioma by Salas et al. https://t.co/XDlxmGnqfl @Geise…
Just published! Phase I Study of #Methylfolate in Recurrent High-Grade #Glioma by Salas et al. https://t.co/XDlxmGnqfl @GeiselMed @VUMChealth #openaccess #glioblastoma https://t.co/yojayBVXOv
RT @vandy_biostat: Hot off the press! Second author is assistant professor Tom Stewart, collaborating with members of @VUMCneurology, @Yale…
Hot off the press! Second author is assistant professor Tom Stewart, collaborating with members of @VUMCneurology, @YaleMed, @TNOncology, @NeurosurgUCSF, @hudsonalpha, @GeiselMed and more. #CancerResearch #SurvivalAnalysis #Bioinformatics
Phase 1 clinical trial https://t.co/JIYnbDyqlz shows for the first time in a human study that the DNA methylome of high-grade glioma, an aggressive brain tumor, can be reprogrammed. Stephen Clark, MD, PhD, of Vanderbilt-Ingram Cancer Center, says it's a fi